2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias: Part 3
10.18501/arrhythmia.2018.008
- Author:
Youngjin CHO
;
Sung Hwan KIM
;
Yoo Ri KIM
;
Yoon Nyun KIM
;
Ju Youn KIM
;
Tae Hoon KIM
;
Gi Byoung NAM
;
Seung Young ROH
;
Kyoung Min PARK
;
Hyoung Seob PARK
;
Hui Nam PAK
;
Eun Jung BAE
;
Seil OH
;
Namsik YOON
;
Man Young LEE
;
Yongkeun CHO
;
Eun Sun JIN
;
Tae Joon CHA
;
Jong Il CHOI
;
Jun KIM
- Publication Type:Review
- MeSH:
Arrhythmias, Cardiac;
Cardiomyopathies;
Cardiomyopathy, Dilated;
Cardiomyopathy, Hypertrophic;
Catheter Ablation;
Catheters;
Coronary Artery Disease;
Death, Sudden, Cardiac;
Defibrillators, Implantable;
Heart Diseases;
Humans;
Myocardial Ischemia;
Tachycardia, Ventricular;
Ventricular Dysfunction, Left
- From:International Journal of Arrhythmia
2018;19(2):82-125
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Treatment of ventricular arrhythmias (VA) usually involves managing the underlying cardiac conditions that cause the arrhythmia. However, managing the underlying disease is often challenging, and catheter ablation, or treatment targeting the VA itself might be required in a few patients. In this article, we explored evidence and recommendations regarding the treatment of VA in patients with structural heart disease focusing on the utilization of catheter ablation in these patients. The administration of optimal medical therapy, insertion of an implantable cardioverter-defibrillator, or resynchronization therapy improves survival in patients with left ventricular dysfunction. The role of catheter ablation in preventing sudden cardiac death remains uncertain in this population. In patients with coronary artery disease, reversing myocardial ischemia via revascularization is important in managing VA. Catheter ablation is recommended in patients with recurrent ventricular tachycardia in a setting of ischemic heart disease. In patients with non-ischemic cardiomyopathies such as dilated cardiomyopathy or hypertrophic cardiomyopathy, catheter ablation may be considered for those presenting with drug-refractory ventricular tachycardia.
